Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

Nature Medicine has published a study examining the normalized membrane ratio of TROP2 as a potential predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer. Sample sizes and specific findings are not provided in the available context.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.